Table 5.
miRNA-mRNA gene targets and significant biological disease and function pathways related to fibroid pathogenesis.
| Biological pathways | miRNA name | mRNA gene target | P-value |
|---|---|---|---|
| Functions | |||
| Cell viability | miR-128-3p, miR-494-3p, miR-10a-5p | BMI1, E2 F3, HMOX1, KIT, KLF4, NF1, NTRK3, PTEN, SNAP25, TGFBR1, TXNIP, WEE1 | 5.38E-06 |
| Cell survival | miR-128-3p, miR-494-3p, miR-10a-5p | ADORA2B, BMI1, E2 F3, HMOX1, KIT, KLF4, NF1, NTRK3, PTEN, SNAP25, TGFBR1, TXNIP, WEE1 | 1.46E-06 |
| Cell cycle progression | miR-128-3p, miR-494-3p, miR-10a-5p | ADORA2B, BMI1, DBI, E2 F3, FGF16, HMOX1, KIT, KLF4, KMT2A, NF1, NTRK3, PTEN, TGFBR1, WEE1 | 2.60E-10 |
| Apoptosis | miR-128-3p, miR-494-3p, miR-10a-5p | ADORA2B, AGO1, BMI1, E2 F3, HMOX1, HOXA1, KIT, KLF4, KMT2A, LDLR, NF1, NTRK3, PTEN, TGFBR1, TXNIP, VSNL1, WEE1 | 1.65E-06 |
| Angiogenesis | miR-128-3p, miR-494-3p, miR-10a-5p | ADORA2B, AGO1, HMOX1, HOXA1, HOXD10, KIT, KLF4, KMT2A, NF1, PTEN, TGFBR1 | 2.88E-07 |
| Cell transformation | miR-128-3p, miR-494-3p, miR-10a-5p | BMI1, KIT, KMT2A, NTRK3, PTEN, USF2 | 2.61E-05 |
| Proliferation of connective tissue cells | miR-128-3p, miR-494-3p, miR-10a-5p | BMI1, HMOX1, KLF4, KMT2A, NF1, NTRK3, PTEN, TXNIP | 5.35E-06 |
| Development of connective tissue cells | miR-128-3p, miR-494-3p, miR-10a-5p | KIT, KLF4, LDLR, TGFBR1, TXNIP | 4.06E-05 |
| Proliferation of fibroblast cell lines | miR-128-3p, miR-494-3p | BMI1, E2 F3, HMOX1, KIT, KMT2A, NTRK3, PTEN, TXNIP | 1.65E-07 |
| Proliferation of stem cells | miR-128-3p, miR-494-3p, miR-10a-5p | AGO1, BMI1, E2 F3, HOXA1, KIT, NF1, PTEN, TGFBR1 | 3.90E-10 |
| Disease pathways | |||
| Tumorigenesis of reproductive tract | miR-128-3p, miR-494-3p, miR-10a-5p | AFF1, DCX, E2 F3, FGF16, HOXA1, HOXD10, KIT, KLF4, KMT2A, LDLR, NF1, NTRK3, PTEN, RELN, SCN3A, TGFBR1, TXNIP, WEE1 | 2.52E-09 |
| Benign tumors | miR-128-3p, miR-494-3p, miR-10a-5p | AFF1, DCX, HMOX1, KIT, KLF4, NF1, PTEN, RELN, WEE1 | 1.90E-06 |
| Differentiation of muscle cells | miR-128-3p, miR-494-3p | LDLR, HMOX1 | 5.00E-15 |
| Smooth muscle tumor | miR-128-3p, miR-494-3p, miR-10a-5p | DCX, KIT, NF1, PTEN, WEE1 | 4.70E-05 |
| Proliferation of muscle cells | miR-128-3p, miR-494-3p, miR-10a-5p | E2 F3, FGF16, HMOX1, KIT, KLF4, NF1, PTEN | 2.38E-06 |
Abbreviations: ADORA2B, adenosine A2b receptor; AFF1, AF4/FMR2 family member 1; AGO1, argonaute RISC component 1; BMI1, BMI1 proto-oncogene, polycomb ring finger; DBI, diazepam binding inhibitor, acyl-CoA binding protein; DCX, doublecortin; E2 F3, E2 F transcription factor 3; FGF16, fibroblast growth factor 16; HOXA1, homeobox A1; HOXD10, homeobox D10; HMOX1, heme oxygenase 1; KIT, KIT proto-oncogene receptor tyrosine kinase; KMT2A, lysine methyltransferase 2A; KLF4, kruppel like factor 4; LDLR, low density lipoprotein receptor; NF1, neurofibromin 1; NTRK3, neurotrophic receptor tyrosine kinase 3; PTEN, phosphatase and tensin homolog; RELN, reelin; SCN3A, sodium voltage-gated channel alpha subunit 3; SNAP25, synaptosome associated protein 25; TGFBR1, transforming growth factor β receptor 1; TXNIP, thioredoxin interacting protein; USF2, upstream transcription factor 2, c-fos interaction; VSNL1, visinin like 1; WEE1, WEE1 G2 checkpoint kinase.